Cellusion’s business progress and fundraising article published in Pharmaceutical Technology.
2023.06.29
Pharmaceutical Technology, providing pharmaceutical trends, news & in-depth feature stories, published an article on the development of our lead program CLS001 (iPS cell-derived corneal endothelial cell substitute) as well as our Series C round financing.
For complete coverage, please visit the website of Pharmaceutical Technology.
https://www.pharmaceutical-technology.com/news/cellusion-shares-pipeline-update-for-eye-disease-stem-cell-therapy/
